Publication date: Sep 01, 2025
We evaluated intramuscular (IM) versus intravenous (IV) administration of tixagevimab/cilgavimab in early COVID-19. Both routes achieved rapid elimination of culturable virus and minimal emergence of resistance. These results support IM delivery as a viable alternative to IV, with important implications for scalable deployment in future viral pandemics.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Antibody | intramuscular administration |
| Culturable | monoclonal antibodies |
| Future | SARS-CoV-2 |
| Pandemics | tixagevimab/cilgavimab |
| Viral | viral culture conversion |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | Infectious Diseases |
| drug | DRUGBANK | Etodolac |
| pathway | REACTOME | Reproduction |
| pathway | REACTOME | Translation |
| disease | IDO | site |
| drug | DRUGBANK | Coenzyme M |
| drug | DRUGBANK | Trestolone |
| disease | IDO | symptom |
| disease | MESH | viral load |
| disease | IDO | infectivity |
| drug | DRUGBANK | Etoperidone |
| disease | MESH | chronic infection |
| disease | IDO | host |
| disease | MESH | immunocompromised host |
| disease | IDO | immunodeficiency |
| drug | DRUGBANK | Palivizumab |
| disease | MESH | emergency |
Original Article
(Visited 8 times, 1 visits today)